Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2007 1
2009 2
2011 4
2012 1
2013 3
2014 1
2015 1
2016 2
2019 3
2020 3
2021 4
2022 5
2023 8
2024 9
2025 11
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

55 results

Results by year

Filters applied: . Clear all
Page 1
Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer.
Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M, Goldman JW, Laktionov K, Kim SW, Kato T, Vu HV, Lu S, Lee KY, Akewanlop C, Yu CJ, de Marinis F, Bonanno L, Domine M, Shepherd FA, Zeng L, Hodge R, Atasoy A, Rukazenkov Y, Herbst RS; ADAURA Investigators. Wu YL, et al. N Engl J Med. 2020 Oct 29;383(18):1711-1723. doi: 10.1056/NEJMoa2027071. Epub 2020 Sep 19. N Engl J Med. 2020. PMID: 32955177 Clinical Trial.
Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC.
Tsuboi M, Herbst RS, John T, Kato T, Majem M, Grohé C, Wang J, Goldman JW, Lu S, Su WC, de Marinis F, Shepherd FA, Lee KH, Le NT, Dechaphunkul A, Kowalski D, Poole L, Bolanos A, Rukazenkov Y, Wu YL; ADAURA Investigators. Tsuboi M, et al. N Engl J Med. 2023 Jul 13;389(2):137-147. doi: 10.1056/NEJMoa2304594. Epub 2023 Jun 4. N Engl J Med. 2023. PMID: 37272535 Clinical Trial.
Adjuvant trastuzumab in HER2-positive breast cancer.
Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A, Crown J; Breast Cancer International Research Group. Slamon D, et al. N Engl J Med. 2011 Oct 6;365(14):1273-83. doi: 10.1056/NEJMoa0910383. N Engl J Med. 2011. PMID: 21991949 Free PMC article. Clinical Trial.
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication.
Miles D, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Campone M, Bondarenko I, Nowecki Z, Errihani H, Paluch-Shimon S, Wardley A, Merot JL, Trask P, du Toit Y, Pena-Murillo C, Revelant V, Klingbiel D, Bachelot T; PERUSE investigators. Miles D, et al. Ann Oncol. 2021 Oct;32(10):1245-1255. doi: 10.1016/j.annonc.2021.06.024. Epub 2021 Jul 2. Ann Oncol. 2021. PMID: 34224826 Free article. Clinical Trial.
Systemic treatment of immune checkpoint inhibitor-induced psoriasis: Inference-based guidance.
Papp KA, Puig L, Beecker J, Chandran V, Claveau J, Cortés J, Dutz J, Hornick NI, Juergens RA, Melosky B, Patel AB, Sauder MB, Sehdev S, Sibaud V, Snow SL. Papp KA, et al. Among authors: sehdev s. J Eur Acad Dermatol Venereol. 2025 Nov;39(11):1881-1894. doi: 10.1111/jdv.20809. Epub 2025 Jul 21. J Eur Acad Dermatol Venereol. 2025. PMID: 40685883 Free PMC article.
Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HER2+ Breast Cancer in Both the Early and Metastatic Setting.
Manna M, Gelmon KA, Boileau JF, Brezden-Masley C, Cao JQ, Jerzak KJ, Prakash I, Sehdev S, Simmons C, Bouganim N, Brackstone M, Cescon DW, Chia S, Dayes IS, Edwards S, Hilton J, Joy AA, Laing K, Webster M, Henning JW. Manna M, et al. Among authors: sehdev s. Curr Oncol. 2024 Oct 24;31(11):6536-6567. doi: 10.3390/curroncol31110484. Curr Oncol. 2024. PMID: 39590115 Free PMC article.
Dedicated anticoagulation management protocols in fragility femoral fracture care - a source of significant variance and limited effectiveness in improving time to surgery: The hip and femoral fracture anticoagulation surgical timing evaluation (HASTE) study.
Farhan-Alanie MM, Dixon J, Irvine S, Walker R, Eardley WGP; HASTE collaborators. Farhan-Alanie MM, et al. Injury. 2024 Aug;55(8):111686. doi: 10.1016/j.injury.2024.111686. Epub 2024 Jun 19. Injury. 2024. PMID: 38976927 Free article.
Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for Clinical Staging of Patients Newly Diagnosed with Breast Cancer.
Cao JQ, Surgeoner B, Manna M, Boileau JF, Gelmon KA, Brackstone M, Brezden-Masley C, Jerzak KJ, Prakash I, Sehdev S, Wong SM, Bouganim N, Cescon DW, Chia S, Dayes IS, Joy AA, Henning JW. Cao JQ, et al. Among authors: sehdev s. Curr Oncol. 2024 Nov 15;31(11):7226-7243. doi: 10.3390/curroncol31110533. Curr Oncol. 2024. PMID: 39590163 Free PMC article.
55 results